Trial Profile
Efficacy and Safety of AbGn-168H in Patients With Active Psoriatic Arthritis: a 24-week, Open-label, Multi-center, Phase II Proof of Principle Trial.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Neihulizumab (Primary)
- Indications Psoriatic arthritis
- Focus Proof of concept; Therapeutic Use
- Sponsors AbGenomics Corporation; AltruBio
- 24 Nov 2020 According to an AltruBio media release, results from this study were presented at the ACR convergence on Nov. 7, 2020.
- 26 Apr 2016 Results (n=20) published in an AbGenomics International media release.
- 28 Jan 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.